Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $8.75.
AUTL has been the topic of several recent analyst reports. Zacks Research upgraded Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th. HC Wainwright increased their price target on Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, May 14th. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 29th. Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a report on Monday, April 20th. Finally, Needham & Company LLC restated a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a report on Thursday, April 9th.
Get Our Latest Stock Report on Autolus Therapeutics
Autolus Therapeutics Stock Performance
Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. Autolus Therapeutics had a negative return on equity of 128.59% and a negative net margin of 311.98%.The firm had revenue of $26.22 million for the quarter, compared to the consensus estimate of $26.27 million. Sell-side analysts predict that Autolus Therapeutics will post -0.97 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. Independent Advisor Alliance purchased a new position in Autolus Therapeutics during the 4th quarter worth $28,000. Marex Group plc purchased a new position in Autolus Therapeutics during the 2nd quarter worth $28,000. Waverly Advisors LLC purchased a new position in Autolus Therapeutics during the 1st quarter worth $37,000. SmartHarvest Portfolios LLC purchased a new position in Autolus Therapeutics during the 4th quarter worth $43,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Autolus Therapeutics during the 3rd quarter worth $46,000. 72.83% of the stock is currently owned by hedge funds and other institutional investors.
Autolus Therapeutics Company Profile
Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.
The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.
Featured Articles
- Five stocks we like better than Autolus Therapeutics
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
